IL165910A0 - Compositions of hyaluronic acid and methods of use - Google Patents

Compositions of hyaluronic acid and methods of use

Info

Publication number
IL165910A0
IL165910A0 IL16591003A IL16591003A IL165910A0 IL 165910 A0 IL165910 A0 IL 165910A0 IL 16591003 A IL16591003 A IL 16591003A IL 16591003 A IL16591003 A IL 16591003A IL 165910 A0 IL165910 A0 IL 165910A0
Authority
IL
Israel
Prior art keywords
compositions
methods
hyaluronic acid
hyaluronic
acid
Prior art date
Application number
IL16591003A
Other languages
English (en)
Original Assignee
Pericor Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pericor Science Inc filed Critical Pericor Science Inc
Publication of IL165910A0 publication Critical patent/IL165910A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043Fluorescein, used in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Eyeglasses (AREA)
IL16591003A 2002-07-03 2003-07-03 Compositions of hyaluronic acid and methods of use IL165910A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39395402P 2002-07-03 2002-07-03
PCT/US2003/021034 WO2004004744A1 (fr) 2002-07-03 2003-07-03 Compositions d'acide hyaluronique et procedes d'utilisation

Publications (1)

Publication Number Publication Date
IL165910A0 true IL165910A0 (en) 2006-01-15

Family

ID=30115663

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16591003A IL165910A0 (en) 2002-07-03 2003-07-03 Compositions of hyaluronic acid and methods of use

Country Status (12)

Country Link
US (1) US20060094643A1 (fr)
EP (1) EP1539193A4 (fr)
JP (2) JP4818608B2 (fr)
CN (3) CN103638040A (fr)
AU (1) AU2003256381A1 (fr)
BR (1) BRPI0312331A2 (fr)
CA (1) CA2491054A1 (fr)
IL (1) IL165910A0 (fr)
MX (1) MXPA05000186A (fr)
NZ (1) NZ537735A (fr)
RU (1) RU2005102604A (fr)
WO (1) WO2004004744A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7722808B2 (en) 2003-09-12 2010-05-25 Novartis Ag Method and kits for sterilizing and storing soft contact lenses
JP2005200386A (ja) * 2004-01-19 2005-07-28 Chisso Corp リパーゼ阻害効果、脂肪吸収抑制効果及びコレステロール吸収抑制効果を有する薬剤
US20060083732A1 (en) * 2004-06-30 2006-04-20 Arlene Gwon Hyaluronic acid in the enhancement of lens regeneration
US20080075756A1 (en) * 2004-06-30 2008-03-27 Advanced Medical Optics, Inc. Enhancement of lens regeneration using materials comprising polymers
US8802651B2 (en) * 2004-06-30 2014-08-12 Abbott Medical Optics Inc. Hyaluronic acid in the enhancement of lens regeneration
FR2873379B1 (fr) * 2004-07-23 2008-05-16 Jerome Asius Procede de preparation d'acide hyaluronique reticule, acide hyaluronique reticule susceptible d'etre obtenu par ledit procede, implant contenant ledit acide hyaluronique reticule, et son utilisation
JP4845359B2 (ja) * 2004-09-16 2011-12-28 弘 竹田 口腔ケア用組成物
DE602006006424D1 (de) * 2005-02-09 2009-06-04 Safilens S R L Ackung zur aufbewahrung und pflege einer kontaktlinse
ITMI20052036A1 (it) * 2005-10-26 2007-04-27 Professional Dietetics Srl Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato
CN101432311A (zh) * 2006-02-28 2009-05-13 诺维信生物聚合物公司 透明质酸衍生物
EP2010100B1 (fr) * 2006-04-27 2018-11-28 Johnson & Johnson Surgical Vision, Inc. Matériaux comprenant des polymères de polysiloxane pour une amélioration de la régénération du cristallin
ITPD20060219A1 (it) * 2006-05-31 2007-12-01 Fidia Farmaceutici Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
JP2007320906A (ja) * 2006-06-01 2007-12-13 Shiseido Co Ltd 小じわ改善剤
JP2008063334A (ja) * 2006-08-10 2008-03-21 Lion Corp 水溶性有効成分の付着化組成物及び水溶性有効成分の付着方法
US8609634B2 (en) 2007-05-16 2013-12-17 Mcneil-Ppc, Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
US9579341B2 (en) 2007-05-16 2017-02-28 Johnson & Johnson Consumer Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US20090036404A1 (en) * 2007-08-02 2009-02-05 Macleod Steven K Ophthalmic compositions comprising a carboxyl-modified fructan or a salt thereof
US8689971B2 (en) 2007-08-31 2014-04-08 Novartis Ag Contact lens packaging solutions
TWI419719B (zh) 2007-08-31 2013-12-21 Novartis Ag 隱形眼鏡產物
US20090068122A1 (en) * 2007-09-06 2009-03-12 Shira Pilch Dentifrice Compositions for Treating Xerostomia
AU2009212321B2 (en) 2008-02-08 2012-04-19 Colgate-Palmolive Company Compositions and methods for the treatment of xerostomia
US20100075420A1 (en) * 2008-03-14 2010-03-25 Anita Saraf Novel Gene Delivery Vectors for Human Mesenchymal Stem Cells
AU2009228217A1 (en) 2008-03-28 2009-10-01 The Regents Of The University Of California Polypeptide-polymer conjugates and methods of use thereof
CN102177180A (zh) 2008-04-04 2011-09-07 犹他州大学研究基金会 烷基化半合成的糖胺聚糖醚及其制备和使用方法
US20100022471A1 (en) * 2008-07-23 2010-01-28 Sage Products Inc. Oral Moisturizer for Alleviating Dry Mouth
EP3246048B1 (fr) 2009-02-18 2024-04-03 Calm Water Therapeutics LLC Utilisation d'un copolymère bifonctionnel pour des applications ophtalmiques
WO2010099543A2 (fr) * 2009-02-27 2010-09-02 Inter-Med, Inc. Compositions et procédés pour la détection d'un néoplasme oral
IT1397246B1 (it) 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica
JP5601805B2 (ja) * 2009-08-24 2014-10-08 キユーピー株式会社 経口用ドライアイ改善剤、ならびに前記経口用ドライアイ改善剤を含む食品組成物および医薬品組成物
KR20130057969A (ko) * 2010-02-22 2013-06-03 에쥐 세라피틱스, 인코포레이티드 뇌의 출혈성 병상을 치료하기 위한 방법 및 조성물
US20110212196A1 (en) * 2010-03-01 2011-09-01 Maine Conservation Medicine Center Therapeutic oil composition containing carvone
ITUD20100112A1 (it) * 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
JP6062917B2 (ja) 2011-03-23 2017-01-18 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション 泌尿器科の炎症の治療及び予防の方法
SG10201602665UA (en) 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow
US20130108550A1 (en) * 2011-10-26 2013-05-02 Abbott Cardiovasculr Systems, Inc. Bioabsorbable Co-Filler for Cerebrovascular Aneurysms
JP5840107B2 (ja) * 2012-06-17 2016-01-06 コスメディ製薬株式会社 ヒアルロン酸ゲル及びその製造方法
KR101498510B1 (ko) * 2012-06-26 2015-03-04 서울대학교산학협력단 히알루론산을 포함하는 인공 타액 조성물
US10011832B2 (en) * 2012-09-05 2018-07-03 Sylentis Sau SiRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US20140178327A1 (en) * 2012-12-21 2014-06-26 Coopervision International Holding Company, Lp Antimicrobial Ophthalmic Devices
PL3613423T3 (pl) 2013-07-10 2023-02-13 Matrix Biology Institute Kompozycje hialuronanu o dużej sprężystości i ich zastosowanie
WO2015036576A1 (fr) * 2013-09-12 2015-03-19 Dsm Ip Assets B.V. Dispositif oculaire
RU2551312C1 (ru) * 2014-04-24 2015-05-20 Людмила Владимировна Уварова Способ восстановления тканей зубочелюстной системы
US10695290B2 (en) * 2014-05-19 2020-06-30 A. Ebbie Soroudi, M.D., M.S., A Professional Medical Corporation Non-irritating, non-blurring, photostable ophthalmic sunscreen composition
EP3154550B1 (fr) 2014-06-15 2021-08-04 Yeda Research and Development Co. Ltd. Traitement de surface par des polymères hydrosolubles et des lipides/liposomes
JP6457281B2 (ja) * 2015-01-29 2019-01-23 学校法人東京電機大学 修飾ヒアルロン酸及び/又はその塩、並びにその製造方法
US20160279108A1 (en) * 2015-02-24 2016-09-29 University Of Kansas Targeted mtor inhibitors
US20180185276A1 (en) * 2015-03-26 2018-07-05 Mitotech S.A. Contact lenses carrying mitochonrially-targeted antioxidants
EP3108874A1 (fr) * 2015-06-26 2016-12-28 TRB Chemedica AG Préparation pharmaceutique pour application à l'oeil
RU2020123728A (ru) * 2015-09-24 2021-01-18 Матрикс Байолэджи Инститьют Композиции гиалуроновой кислоты с высокоэластичными свойствами и способы их применения
DK3383631T3 (da) 2015-12-03 2019-10-28 Novartis Ag Emballeringsopløsninger til kontaktlinser
CA3022905A1 (fr) 2015-12-09 2017-06-15 The Regents Of The University Of California Methodes de traitement d'une maladie ou d'un trouble oculaire
DE102016204472A1 (de) * 2016-03-17 2017-09-21 Ursapharm Arzneimittel Gmbh Kit zur kosmetischen Behandlung des Auges und der Haut und Kosmetikum zur Anwendung am Auge und auf der Haut
CA3049286C (fr) * 2016-04-25 2022-08-30 Mizhou Hui Application de fragments d'acide hyaluronique a faible masse moleculaire
EP3241895A1 (fr) * 2016-05-04 2017-11-08 ETH Zürich, ETH Transfer Hydrogels d'hyaluronane de poids moleculaire eleve induits par transglutaminase
AU2016413933B2 (en) 2016-07-06 2023-06-15 Calm Water Therapeutics Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
IT201600079633A1 (it) * 2016-07-28 2018-01-28 Fidia Farm Spa Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico
WO2018053111A1 (fr) 2016-09-15 2018-03-22 University Of Utah Research Foundation Compositions de gélification in situ pour le traitement ou la prévention d'une inflammation et d'une lésion tissulaire
KR20190068575A (ko) * 2016-10-14 2019-06-18 이콤 메디칼 게엠베하 안구 표면 항상성의 확립, 회복 및 보존 방법
JP6338715B2 (ja) * 2017-02-06 2018-06-06 ナンヤン テクノロジカル ユニヴァーシティー 眼用及び医療用の重合性組成物及びそれを重合して得られる抗菌性組成物
JP6868314B2 (ja) * 2017-07-26 2021-05-12 ユーレー カンパニー リミテッドYoureh Co.,Ltd. ヒアルロン酸−カルシウム及びポリリシンを含む創傷被覆材及びその製造方法
US11129862B2 (en) 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
WO2020057606A1 (fr) * 2018-09-20 2020-03-26 The Hong Kong University Of Science And Technology Compositions de gouttes oculaires
CN118512390A (zh) * 2018-09-20 2024-08-20 香港科技大学 滴眼剂组合物
CN111228653A (zh) 2018-11-13 2020-06-05 格莱科米拉治疗公司 用电离辐射加强癌症治疗的方法
JP2022514257A (ja) * 2018-12-13 2022-02-10 アイノス,インコーポレイテッド ドライアイ疾患の治療のための局所点眼製剤におけるlxrアゴニスト
US20220354633A1 (en) * 2019-05-07 2022-11-10 Cornell University Temporary synthetic carrier for corneal tissue insertion and tissue delivery
CN112494710B (zh) * 2019-09-16 2021-12-14 天津大学 一种转谷氨酰胺酶促交联的双网络粘合剂及其制备方法
RU2716023C1 (ru) * 2019-09-20 2020-03-05 Акционерное Общество "Свобода" (Ао "Свобода") Активный комплекс для приготовления композиций по уходу за полостью рта
MX2022010104A (es) 2020-02-18 2022-09-05 Sunstar Americas Inc Composicion para el cuidado bucal.
KR102479119B1 (ko) * 2020-10-07 2022-12-19 주식회사 휴메디솔 생체적합성 mpc 고분자 기반의 콘택트렌즈 다기능 용액 및 이의 제조방법
CN115317505A (zh) * 2021-05-10 2022-11-11 傅毓秀 玻尿酸用于制备治疗肺纤维化药剂的用途
EP4180032A1 (fr) * 2021-11-16 2023-05-17 National University of Ireland Galway Traitement par modulation des tissus excitables et des nerfs
TWI815436B (zh) * 2022-05-10 2023-09-11 長庚大學 使用聚離胺酸奈米粒子來治療乾眼症
CN118286154A (zh) * 2024-03-19 2024-07-05 山东焦点福瑞达生物股份有限公司 一种针对男性私处的植物透明质酸护理液及其制备方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US559104A (en) * 1896-04-28 Street-railroad-car advertising device
US2583096A (en) * 1949-01-15 1952-01-22 Searle & Co Process for the production of high viscosity hyaluronic acid
US3792164A (en) * 1970-03-31 1974-02-12 Chemway Corp Ophthalmic composition comprising water-soluble alkaloid salts of polyuronic acids
US3870791A (en) * 1972-04-24 1975-03-11 Heskel M Haddad Solid state ophthalmic medication delivery method
JPS5318520B2 (fr) * 1972-07-05 1978-06-15
US4003991A (en) * 1974-08-27 1977-01-18 National Patent Development Corporation Ophthalmic formulation
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
LU76955A1 (fr) * 1977-03-15 1978-10-18
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
US4328803B1 (en) * 1980-10-20 1994-01-11 Opthalmic Systems, Inc. Opthalmological procedures
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4443432A (en) * 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
JPS5945890A (ja) * 1982-09-09 1984-03-14 Toyo Jozo Co Ltd 新規抗生物質アクミマイシンおよびその製造法
US5002582A (en) * 1982-09-29 1991-03-26 Bio-Metric Systems, Inc. Preparation of polymeric surfaces via covalently attaching polymers
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4517295A (en) * 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
GB8318403D0 (en) * 1983-07-07 1983-08-10 Sutherland I W Gel-forming polysaccharides
US4795436A (en) * 1983-11-14 1989-01-03 Bio-Mimetics, Inc. Bioadhesive composition and method of treatment therewith
US4983392A (en) * 1983-11-14 1991-01-08 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US5316926A (en) * 1983-11-25 1994-05-31 Miles Inc. Method for the microbiological production of non-antigenic hyaluronic acid
US4500676A (en) * 1983-12-15 1985-02-19 Biomatrix, Inc. Hyaluronate modified polymeric articles
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5409904A (en) * 1984-11-13 1995-04-25 Alcon Laboratories, Inc. Hyaluronic acid compositions and methods
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
JPS61253065A (ja) * 1985-05-02 1986-11-10 片倉チツカリン株式会社 キトサン誘導体およびコラ−ゲンの複合材の医用材料およびその製造法
US5202431A (en) * 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5034514A (en) * 1986-03-17 1991-07-23 Cetus Corporation Novel cross-linking agents
US4840626A (en) * 1986-09-29 1989-06-20 Johnson & Johnson Patient Care, Inc. Heparin-containing adhesion prevention barrier and process
IL80298A (en) * 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
EP0280155B1 (fr) * 1987-02-25 1992-05-20 Hoechst Aktiengesellschaft Microencapsulation de substances biologiquement actives
US5108759A (en) * 1987-04-01 1992-04-28 Ranney David F Endothelial envelopment drug carriers
US6387379B1 (en) * 1987-04-10 2002-05-14 University Of Florida Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like
US5079236A (en) * 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
IL83687A (en) * 1987-08-30 1995-03-30 Yeda Res & Dev Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions
US5017229A (en) * 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US6174999B1 (en) * 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5510329A (en) * 1988-04-26 1996-04-23 Ramot University For Applied Research And Industrial Development Ltd. Preparations for the treatment of eyes
US4920104A (en) * 1988-05-16 1990-04-24 Medchem Products, Inc. Sodium hyaluronate composition
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
CA2006060A1 (fr) * 1988-12-20 1990-06-20 Michael D. Pierschbacher Conjugats polypeptide-polymere actifs dans la cicatrisation des plaies
US5783691A (en) * 1989-02-08 1998-07-21 Biomatrix, Inc. Crosslinked hyaluronate gels, their use and method for producing them
US5132230A (en) * 1989-03-28 1992-07-21 Isolab, Inc. Primary standard and method of making secondary standards for calibration of glycated protein assays
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
SE465950B (sv) * 1989-10-23 1991-11-25 Medinvent Sa Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1994007505A1 (fr) * 1991-07-03 1994-04-14 Norpharmco Inc. Utilisation de l'acide hyaluronique sous differentes formes contre la recidive de la stenose arterielle
EP0607339A4 (en) * 1991-10-09 1994-08-10 Hawaii Chemtect Int Field kit for detecting analytes.
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US6235313B1 (en) * 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5645827A (en) * 1992-09-30 1997-07-08 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
WO1994018834A1 (fr) * 1993-02-16 1994-09-01 Virginia Tech Intellectual Properties, Inc. Conjugaison polyelectrolyte-adn et transformation genetique d'un animal
EP0615745B1 (fr) * 1993-02-19 1997-05-02 Howard Green Compositions contenant des protéines à partir de corneocytes
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5773577A (en) * 1994-03-03 1998-06-30 Protein Polymer Technologies Products comprising substrates capable of enzymatic cross-linking
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
FR2719316B1 (fr) * 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
SE9401806D0 (sv) * 1994-05-26 1994-05-26 Pharmacia Ab Method and means for the production of hyaluronic acid
IT1273011B (it) * 1994-07-25 1997-07-01 Trhecnopharma S A Preparato oftalmico per l'uso come lacrima artificiale
US5490980A (en) * 1994-09-28 1996-02-13 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Covalent bonding of active agents to skin, hair or nails
US5620013A (en) * 1994-10-21 1997-04-15 American Cyanamid Company Method for destroying residual lens epithelial cells
IT1274984B (it) * 1994-12-09 1997-07-29 Technopharma Sa Soluzioni viscosizzate con ialuronato di sodio per l'uso come fluido maschera nella fotocheratectomia terapeutica mediante laser a accimeri
US5510102A (en) * 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US5817303A (en) * 1995-05-05 1998-10-06 Protein Polymer Technologies, Inc. Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer
US6284284B1 (en) * 1995-06-06 2001-09-04 Advanced Tissue Sciences, Inc. Compositions and methods for production and use of an injectable naturally secreted extracellular matrix
DE69632684T2 (de) * 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
US6265389B1 (en) * 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
EP0852501B1 (fr) * 1995-09-28 2004-12-01 Sangstat Medical Corporation Utilisation d'acide hyaluronique en qualite d'agent immunosuppresseur
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
ES2420106T3 (es) * 1995-12-18 2013-08-22 Angiodevice International Gmbh Composiciones de polímeros reticulados y métodos para su uso
US6261584B1 (en) * 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
ATE199908T1 (de) * 1996-12-16 2001-04-15 Nederlanden Staat Verfahren zur kupplung von polysacchariden und proteinen
US5861149A (en) * 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
US6229009B1 (en) * 1997-08-29 2001-05-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Polycarboxylic based cross-linked copolymers
US6267957B1 (en) * 1998-01-20 2001-07-31 Howard Green Attaching agents to tissue with transglutaminase and a transglutaminase substrate
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
IL137128A0 (en) * 1998-01-30 2001-07-24 R Tech Ueno Ltd Ophthalmic compositions containing tetrahydroquinazoline derivatives
US6200595B1 (en) * 1998-04-24 2001-03-13 Kuraray Co., Ltd. Medical adhesive
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6335029B1 (en) * 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
EP1117378A2 (fr) * 1998-10-05 2001-07-25 The Penn State Research Foundation Compositions et procedes permettant d'augmenter l'internalisation cellulaire a mediation par les recepteurs
EP1140021B1 (fr) * 1998-12-23 2004-08-04 Idea Ag Formulation amelioree pour l'application topique non invasive in vivo
AU3327000A (en) * 1999-03-24 2000-10-09 Seikagaku Corporation Artificial saliva
JP2001081103A (ja) * 1999-09-13 2001-03-27 Denki Kagaku Kogyo Kk ヒアルロン酸結合薬剤
US6200599B1 (en) * 1999-10-07 2001-03-13 The Regents Of The University Of California Ortho ester lipids
US6893462B2 (en) * 2000-01-11 2005-05-17 Regeneration Technologies, Inc. Soft and calcified tissue implants
US6348508B1 (en) * 2000-04-04 2002-02-19 Bausch & Lomb Incorporated Method for treating dry eye
WO2001086002A2 (fr) * 2000-05-09 2001-11-15 Genetics Institute, Llc Compositions, kits, et procedes pour l'identification, l'evaluation, la prevention, et la therapie du psoriasis
IL140844A0 (en) * 2001-01-10 2002-02-10 Polygene Ltd Cationic polysaccharide compositions

Also Published As

Publication number Publication date
RU2005102604A (ru) 2005-09-10
EP1539193A1 (fr) 2005-06-15
CN1671400A (zh) 2005-09-21
CA2491054A1 (fr) 2004-01-15
CN102178692A (zh) 2011-09-14
JP2006502988A (ja) 2006-01-26
NZ537735A (en) 2006-08-31
EP1539193A4 (fr) 2010-05-05
US20060094643A1 (en) 2006-05-04
JP4818608B2 (ja) 2011-11-16
BRPI0312331A2 (pt) 2016-06-28
JP2010270126A (ja) 2010-12-02
WO2004004744A1 (fr) 2004-01-15
CN103638040A (zh) 2014-03-19
MXPA05000186A (es) 2005-08-17
AU2003256381A1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
IL165910A0 (en) Compositions of hyaluronic acid and methods of use
AU2003259735A8 (en) Small-mer compositions and methods of use
AU2003257937A8 (en) Methods and compositions for treatment of dermal conditions
HK1210032A1 (en) Compositions and methods of delivery of pharmacological agents
HK1079789A1 (zh) 血管靜態毒性試劑及其使用方法
IL166608A0 (en) Anti-microbial compositions and methods of using same
EP1606285A4 (fr) Inhibiteurs de ido et procedes d'utilisation de ceux-ci
EP1562225A4 (fr) Composition de nettoyage et procede pour nettoyer avec cette composition
AU2003299441A8 (en) Nf-hev compositions and methods of use
EP1696910A4 (fr) Compositions et procedes pour traiter une fibrose
AU2003220361A8 (en) Benzamides and compositions benzamides for use as fungizide
IL205407A0 (en) Hyaluronic acid antagonist and inhibitor compositions and uses thereof
AU2003301240A8 (en) Skin cleanser compositions and methods of use
AU2003287443A8 (en) Compositions and methods for pain reduction
EP1476150A4 (fr) Carboxyfullerenes et procedes d'utilisation de ceux-ci
GB0208081D0 (en) Skincare compositions and methods
EP1663255A4 (fr) Compositions de withanamide and withanolide et procede d'utilisation de celles-ci
AU2003239868A8 (en) Sunscreen compositions and methods of use thereof
EP1625141A4 (fr) Compositions a base de grp94 et procedes d'utilisation associes
GB0324523D0 (en) Compositions and methods of treatment
EP1534293A4 (fr) Compositions anti-inflammatoires et procedes d'utilisation
AU2003215264A8 (en) Compositions and methods for delivery of skin cosmeceuticals
AU2003294684A8 (en) Ketoprofen compositions and methods of making them
AU2003282593A8 (en) Polyphenolamine composition and method of use
EP1414427A4 (fr) Compositions a base de kavalactone et leurs procedes d'utilisation